Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVWZN1)

Drug Name

F-200 Drug Info

Synonyms

Eos-200-F; Anti-alpha-5/beta-1 integrin Ab Fragment, PDL; Anti-alpha-5/beta-1 integrin Fab, PDL; Anti-alpha-5/beta-1 integrin Fab, Protein Design Labs

Indication

Disease Entry	ICD 11	Status	REF
Ocular disease	1F00.1Z	Terminated	[1]

Cross-matching ID

PubChem CID: 16660135
TTD Drug ID: DMVWZN1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin alpha-5/beta-1 (ITGA5/B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATN-161	DM4T9RS	Renal cell carcinoma	2C90	Phase 2	[3]
Volociximab	DMNQG24	Non-small-cell lung cancer	2C25.Y	Phase 2	[4]
AMEP	DMFELMQ	Melanoma	2C30	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-5/beta-1 (ITGA5/B1)	TTH4QIS	ITA5_HUMAN-ITB1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018439)
2	US patent application no. 8,541,413, Sustained release eye drop formulations.
3	A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80.
4	Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.
5	Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90.